GUIAS HIPERTENSION ARTERIAL.indb - Scc

Revista Colombiana de Cardiología
Febrero 2007
National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure. The JNC 7 report. JAMA 2003; 289: 2560-2572.
5. European Society of Hypertension-European Society of Cardiology Guidelines
Committee. 2003 European Society of Hypertension-European Society of Cardiology
guidelines for the management of arterial hypertension. J Hypertens
2003; 21: 1011-1053.
6. World Health Organization-International Society of Hypertension Guidelines
for the Management of Hypertension. Guidelines Subcommittee. J Hypertens
1999; 17: 151-183.
7. The SOLVD investigators. Effect of enalapril on survival in patients with reduced
left ventricular ejection fractions and congestive heart failure. N Engl J Med
1991; 325: 293-302.
8. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators. Effect of ramipril
on mortality and morbidity of survivors of acute myocardial infarction with clinical
evidence of heart failure. Lancet 1993; 342: 821-828.
9. Kober L, Torp-Pedersen C, Carlsen J, et al. A clinical trial of the angiotensinconverting-enzyme
inhibitor trandolapril in patients with left ventricular dysfunction
after myocardial infarction. N Engl J Med 1995; 333: 1670-1676.
10. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and
morbidity in patients with left ventricular dysfunction after myocardial infarction.
Results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992;
327: 669-677.
11. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme
inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart
Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:
145-153.
12. The EUropean trial on Reduction Of cardiac events with Perindopril in stable
coronary Artery disease Investigators (The EUROPA Study). Lancet 2003; 362:
782-788.
13. Pfeffer MA, Mc Murray J, Velásquez EJ, et al. Valsartan, captopril or both in
myocardial infarction complicated by heart failure, left ventricular dysfunction
or both. N Engl J Med 2003; 349: 1893-1906.
14. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of
macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.
BMJ 1998; 317: 703-713.
15. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with
macrovascular and microvascular complications of type 2 diabetes (UKPDS 36):
prospective observational study. BMJ 2000; 321: 412-419.
16. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. CAPPP Study Group.
Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients
on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based
treatment regimen: A subanalysis of the Captopril Prevention Project.
Diabetes Care 2001; 24: 2091-2096.
17. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus
Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with
hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
18. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new
diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969.
Vol. 13 Suplemento 1
ISSN 0120-5633
237
19. Staessen JA, Wang J, Thijs L. Cardiovascular prevention and blood pressure
reduction; a qualitative overview updated until 1 March 2003. J Hypertens
2003; 21:1055-1076.
20. Dahlof B, Sever PS, Poulter NR, et al, for the ASCOT Investigators. Prevention of
cardiovascular events with an antihypertensive regimen of amlodipine adding
perindopril as required versus atenolol adding bendroflumethiazide as required,
in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm
(ASCOT-BPLA): A multicentre randomized controlled trial. Lancet 2005; 366:
895-906.
21. Sever PS, Dahlof B, Pulter NR, et al; for the ASCOT Investigators. Prevention
of coronary and stroke events with atorvastatin in hypertensive patients who
have average or lower-than-average cholesterol concentrations, in the Anglo-
Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a
multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
22. Libby P. The forgotten majority: Unfinished business in cardiovascular risk reduction.
J Am Coll Cardiol 2005; 46: 1225-1228.
23. Bakris GL, Bhandaru S, Akerstrom V, Re RN. ACE inhibitor mediated attenuation of
mesangial cell growth. A role for endothelin. Am J Hypertens 1994; 7: 583-590.
24. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting-enzyme inhibitors
and progression of nondiabetic renal disease. A meta-analysis of patient-level
data. Ann Intern Med 2001; 135: 73-87.
25. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor
antagonist irbesartan in patients with nephropathy due to type
2 diabetes. N Engl J Med 2001; 345: 851-860.
26. Brenner B, Cooper M, De Zeeuw D, et al. Effects of losartan on renal and
cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N
Engl J Med 2001; 345: 861-869.
27. PROGRESS Collaborative Study Group. Randomised trial of a perindopril-based
blood-pressure-lowering regimen among 6105 individuals with previous stroke
or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
28. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists´
Collaboration. Effects of ACE inhibitors, calcium antagonists, and other
blood-pressure-lowering drugs: results of prospectively designed overviews of
randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration.
Lancet 2000; 356: 1955-1964.
29. Márquez G, Sierra ID, Mendivil CO. Present status of the converting enzyme
inhibitors as anti-hypertensive medications. Acta Med Col 2004; 29: 88-94.
30. Arnett DK, Davis BR. Ford CE, et al. Pharmacogenetic association of the angiotensin-converting
enzyme insertion/deletion polymorphism on blood pressure
and cardiovascular risk in relation to antihypertensive treatment: the Genetics
of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005; 111:
3374-3383.
31. Doulton TWR, He FJ, MacGregor GA. Systematic review of combined angiotensinconverting
enzyme inhibition and angiotensin receptor blockade in hypertension.
Hypertension 2005; 45: 880-886.
32. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade
of the renin-angiotensin system reduces the incidence of new-onset diabetes.
J Hypertens 2005; 23: 463-473.